Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Sarcoma × chiauranib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 2 Recurrence 2 Ovarian Neoplasms 2 Sarcoma 1 Lymphoma, Non-Hodgkin 1 Carcinoma, Hepatocellular 1

Interventions

Doxorubicin 68 Ifosfamide 46 Filgrastim 36 Radiotherapy 33 Gemcitabine 31 Cyclophosphamide 29 Vincristine 21 Etoposide 21 Docetaxel 19 Cisplatin 19 pazopanib 18 Trabectedin 18 Carboplatin 15 Peripheral Blood Stem Cell Transplantation 12 pembrolizumab 11 Sorafenib 11 Mesna 11 Melphalan 11 Irinotecan 11 Sirolimus 10 Granulocyte Colony-Stimulating Factor 10 pegfilgrastim 9 eribulin 9 Topotecan 9 Paclitaxel 9 Bevacizumab 9 Temozolomide 8 Dactinomycin 8 Surgical Procedures, Operative 7 Methotrexate 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05497843 2025-04-03

Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

Chipscreen Biosciences, Ltd.

Phase 2 Completed

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡